Additionally, miR-221 and miR-222 are modulated by EGF and mesenchymal-epithelial transition (MET) proto-oncogene receptors in tyrosine kinase inhibitor-resistant NSCLC, further contributing to cancer progression. This evidence concerns the gene EGF and cancer.